Georgia is currently home to 1930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
NCT06679855
Recruiting
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Gender:
ALL
Ages:
3 months and below
Trial Updated:
05/20/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Post-ligation Cardiac Syndrome
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/20/2025
Locations: Private Practice - Dr. David Kavtaradze- Site Number : 8400081, Cordele, Georgia
Conditions: Asthma
Register for Updates
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS
NCT06617429
Recruiting
The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).
Gender:
ALL
Ages:
Between 4 years and 17 years
Trial Updated:
05/20/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Angelman Syndrome
Register for Updates
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
NCT06555783
Recruiting
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/20/2025
Locations: Alkermes Investigator Site, Atlanta, Georgia
Conditions: Narcolepsy Type 2
Register for Updates
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06362265
Recruiting
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/20/2025
Locations: Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University Cancer & Blood Center, LLC, Athens, Georgia
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Register for Updates
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/20/2025
Locations: CenExel iResearch, LLC, Decatur, Georgia
Conditions: Obesity, Overweight
Register for Updates
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
05/20/2025
Locations: Children's Healthcare of Atlanta, Inc. at Egleston, Atlanta, Georgia
Conditions: Neoplasms, Child, Adolescent
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/20/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/20/2025
Locations: Southeast Retina Center, P.C., Augusta, Georgia
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
Study of LYL314 in Aggressive Large B-Cell Lymphoma
NCT05826535
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Register for Updates